Here are the DEF 14A proxy statements from LB Pharmaceuticals Inc (LBRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Investors will elect three Class I directors and ratify the appointment of BDO USA, P.C. as independent auditor for the year ending December 31, 2026.
The company has a classified nine‑member board and states that a majority of directors are independent under Nasdaq rules, with Scott Garland serving as independent chair. Committees oversee audit, compensation, and governance, and the proxy details director qualifications, independence determinations, and risk‑oversight responsibilities.
The filing outlines executive pay, including 2025 total compensation of $11,884,985 for CEO Heather Turner, largely driven by stock options, and explains annual bonus targets of 55% of salary for the CEO and 40% for key officers. It also discloses severance and change‑in‑control protections, and shows BDO audit fees of $616,325 in 2025 and total fees of $658,325.